Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of LY2216684 adjunctive to SSRI in partial responders with major depressive disorder
NL-OMON36315Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of edivoxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Primary endpoints: Long-term safety and tolerability, Discontinuation rates and 5 more. Started Jul 2011; status: active, not recruiting.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON36315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36315.